Hello. Sign In
Standards Store




Look Inside

CLSI VET05

Revision R, September 2011

Complete Document

Generation, Presentation, and Application of Antimicrobial Susceptibility Test Data for Bacteria of Animal Origin; A Report

Includes all amendments and changes through Reaffirmation Notice , April 2016


View Abstract
Product Details
Document History

Detail Summary

Active, Most Current

EN
Additional Comments:
VOL 31; NO 17
Format
Details
Price (USD)
PDF
Single User
$140.00
Print
In Stock
$147.00
Add to Cart

Product Details:


Description / Abstract:

This report provides a review of current applications of susceptibility test data generated using CLSI methodology for bacteria of animal origin and recommendations for summarizing, presenting, and applying the data. More specifically, the report provides an overview of the CLSI veterinary antimicrobial susceptibility testing (VAST) approach to the use of reference methodology, quality control (QC), and establishment and use of clinical breakpoints and epidemiological cutoff values (ECVs). Recommendations for the presentation of minimal inhibitory concentrations (MICs) or zone inhibition data in frequency histograms and scatter plots are provided, in addition to recommendations for the use of ECVs and/or CLSI clinical breakpoints. A review of various applications of surveillance programs is provided, with clarification of descriptive summary statistics of MIC frequency histograms (eg, MIC50, MIC90, geometric mean), and recommended standardized approaches.

The report also provides a review of several select programs that monitor antimicrobial susceptibility in bacteria of animal origin (eg, Canadian Integrated Program for Antimicrobial Resistance Surveillance [CIPARS], Centre Européen d’Etudes pour la Santé Animale [CEESA], Danish Integrated Antimicrobial Resistance Monitoring and Research Programme [DANMAP], GERM-Vet, Monitoring of Antimicrobial Resistance and Antibiotic Usage in Animals in the Netherlands [MARAN], US National Antimicrobial Resistance Monitoring System [NARMS]) with regard to methods and data presentation and interpretation. For comparison purposes, a similar review is provided for programs monitoring antimicrobial susceptibility in bacteria of human origin (eg, European Antimicrobial Resistance Surveillance Network [EARS-Net], SENTRY Antimicrobial Surveillance Program). This report is not intended to provide guidance for human antimicrobial surveillance programs.

Finally, consideration is given to the intended use of any antimicrobial resistance (AMR) surveillance program. The usual goal in collecting antimicrobial susceptibility data is to detect the early emergence of resistance for a given bacterial species/antimicrobial combination that may be used for the following purposes:


  • Provide a basis for policy recommendations for animal and public health.


  • Generate data that may guide the design of further studies.


  • Provide information for prescribing practices and prudent-use recommendations.


  • Determine the prevalence or trend in prevalence of reduced susceptibility (or resistance) to a certain antimicrobial in a defined population.


  • Detect emergence of AMR (eg, particular phenotypes).


  • Identify the need for potential intervention.


  • Assess the impact of intervention(s).


  • Identify the emergence of new mechanisms of resistance.